

COLLEGIATE BOARD RESOLUTION No. 970 OF 19 MARCH 2025

Provides for the updating of Annex I (Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control) of SVS/MS Ordinance No. 344 of 12 May 1998.

The Collegiate Board of Directors of the Brazilian Health Regulatory Agency, in the use of the attributions vested in it under Article 15, item III, and Article 7, item III of Law no. 9,782 of 26 January 1999, Article 66 of Law no. 11,343 of 23 August 2006, Article 14 of Decree no. 5,912 of 27 September 2006, and Article 20 of Decree no. 8,077 of 14 August 2013, and considering the provisions of Article 187, item VI, Paragraphs 1 and 3 of the Internal Regulation approved by Collegiate Board Resolution – RDC no. 585 of 10 December 2021, adopts the following Collegiate Board Resolution, as decided upon in a meeting held on 17 March 2025, and I, Acting Director-President, determine its publication.

Article 1. Publish the update of Annex I (Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control) of SVS/MS Ordinance No. 344 of 12 May 1998, republished in the Federal Official Gazette of 1 February 1999, establishing the following changes, as provided for in Annex I of this Resolution.

I. INCLUSION

- 1.1. List "B1": alfaxalone
- 1.2. List "B1": lemborexant
- 1.3. List "C5": addendum 5
- 1.4. List "D1": addendum 10
- 1.5. List "F1": N,N-dimethylamino etonitazene

II. AMENDMENT

- 2.1. List "B1": addendum 11

Art. 2 This Resolution shall come into force on the date of its publication.

Rômison Rodrigues Mota

Acting Director-President

ANNEX I

MINISTRY OF HEALTH

BRAZILIAN HEALTH REGULATORY AGENCY

GENERAL OFFICE FOR MONITORING PRODUCTS SUBJECT TO HEALTH SURVEILLANCE

UPDATE NO. 94

LISTS FROM SVS/MS ORDINANCE NO. 344 OF 12 MAY 1998 (FEDERAL OFFICIAL GAZETTE OF 1/FEB/99)

LIST – A1

LIST OF NARCOTIC SUBSTANCES

(Subject to Prescription Notification "A")

1. Acetylmethadol
2. Alphacetylmethadol
3. Alphameprodine
4. Alphamethadol
5. Alphaprodine
6. Alfentanil
7. Allylprodine
8. Anileridine
9. Bezitramide
10. Benzethidine
11. Benzylmorphine
12. Benzoylmorphine
13. Betacetylmethadol
14. Betameprodine
15. Betamethadol
16. Betaprodine
17. Buprenorphine
18. Butorphanol
19. Clonitazene
20. Codoxime

21. Concentrate of poppy straw
22. Dextromoramide
23. Diampromide
24. Diethylthiambutene
25. Diphenoxylate
26. Difenoxin
27. Dihydromorphine
28. Dimepheptanol (methadol)
29. Dimenoxadol
30. Dimethylthiambutene
31. Dioxaphetyl
32. Dipipanone
33. Drotebanol
34. Ethylmethylthiambutene
35. Etonitazene
36. Etoxidine
37. Phenadoxone
38. Phenampromide
39. Phenazocine
40. Phenomorphan
41. Phenoperidine
42. Fentanyl
43. Furethidine
44. Hydrocodone
45. Hydromorphinol
46. Hydromorphone
47. Hydroxypethidine
48. Methadone intermediate (4-cyano-2-dimethylamino-4,4-diphenylbutane)
49. Moramide intermediate (2-methyl-3-morpholine-1,1-diphenylpropane carboxylic acid)
50. Pethidine intermediate A (4-cyano-1-methyl-4-phenylpiperidine)
51. Pethidine intermediate B (4-phenylpiperidine-4-carboxylic acid ethyl ester)

52. Pethidine intermediate C (1-methyl-4-phenylpiperidine-4-carboxylic acid)
53. Isomethadone
54. Levophenacymorphan
55. Levomethorphan
56. Levomoramide
57. Levorphanol
58. Methadone
59. Metazocine
60. Methyldesorphine
61. Methyldihydromorphine
62. Metopon
63. Myrophine
64. Morpheridine
65. Morphine
66. Morinamide
67. Nicomorphine
68. Noracymethadol
69. Norlevorphanol
70. Normethadone
71. Normorphine
72. Norpipanone
73. N-oxycodone
74. N-oxymorphine
75. Opium
76. Oripavine
77. Oxycodone
78. Oxymorphone
79. Pethidine
80. Piminodine
81. Piritramide
82. Proheptazine

83. Properidine
84. Racemethorphan
85. Racemoramide
86. Racemorphan
87. Remifentanil
88. Sufentanil
89. Tapentadol
90. Thebacon
91. Thebaine
92. Tilidine
93. Trimeperidine
94. Viminol

ADDENDUM:

1) The following are also controlled:

1.1. Salts, ethers, esters, and isomers (except the isomers dextromethorphan, (+) 3-methoxy-N-methylmorphinan, and Dextrorphan, (+) 3-hydroxy-N-methylmorphinan) of the substances listed above, whenever their existence is possible;

1.2. Salts of ethers, esters, and isomers (except the isomers dextromethorphan, (+) 3-methoxy-N-methylmorphinan, and Dextrorphan, (+) 3-hydroxy-N-methylmorphinan) of the substances listed above, whenever their existence is possible.

2) preparations based on diphenoxylate, containing per dosage unit no more than 2.5 milligrams of diphenoxylate calculated as a base, and a quantity of atropine sulfate equivalent to at least 1.0% of the quantity of diphenoxylate, are subject to a SPECIAL CONTROL PRESCRIPTION, in 2 (two) copies and the labeling and package insert must present the following sentence: "SALE UNDER MEDICAL PRESCRIPTION – IT MAY ONLY BE SOLD WITH RETENTION OF THE PRESCRIPTION".

3) opium-based preparations containing up to 5 milligrams of anhydrous morphine per milliliter, that is, up to 50 milligrams of opium, are subject to a SPECIAL CONTROL PRESCRIPTION, in 2 (two) copies, and the labeling and package insert must contain the following phrase: "SALE UNDER MEDICAL PRESCRIPTION – IT MAY ONLY BE SOLD WITH RETENTION OF THE PRESCRIPTION".

4) the marketing and manipulation of all medications containing opium and its synthetic derivatives and diphenoxylate hydrochloride and their combinations, in liquid pharmaceutical forms or in syrup for pediatric use, is prohibited (SVS/MS Ordinance No. 106 of 14 September 1994 – Federal Official Gazette of 19/Sep/94).

5) medicinal preparations in the pharmaceutical form of controlled-release tablets based on oxycodone, containing no more than 40 milligrams of this substance, per dosage unit, are subject to a SPECIAL CONTROL PRESCRIPTION, in 2 (two) copies and the labeling and package insert must contain the following phrase: "SALE UNDER MEDICAL PRESCRIPTION – IT MAY ONLY BE SOLD WITH RETENTION OF THE PRESCRIPTION".

6) the prohibited isomer alpha-PVP, which is listed in List "F2" of this regulation, is excluded from the controls related to this List.

7) the isomers listed by name in another List of this regulation are excluded from the controls related to this List.

8) medicinal preparations in the pharmaceutical form of transdermal patches containing buprenorphine in an adhesive polymer matrix, that is, without an active substance reservoir, are subject to a SPECIAL CONTROL PRESCRIPTION in 2 (two) copies and the labeling and package insert must contain the following sentence: "SALE UNDER MEDICAL PRESCRIPTION – IT MAY ONLY BE SOLD WITH RETENTION OF THE PRESCRIPTION".

9) the import and export of analytical standards based on the substances butorphanol, morinamide, tapentadol and viminol, in which the quantity of the active substance subject to special control does not exceed 500 mg per unit, does not require an Import Authorization and Export Authorization, respectively. The provisions of this addendum also apply to analytical standards based on salts, ethers, esters, and isomers, as well as salts of ethers, esters, and isomers, of the substances mentioned, unless they are explicitly excepted or included in more restricted control lists and provided that the quantity of the active ingredient subject to special control does not exceed the specified limit.

10) Isomers not listed by name and which are components of medicines granted marketing authorization by Anvisa, as well as medicines containing them, are excluded from the controls referred to in this list.

LIST – A2

LIST OF NARCOTIC SUBSTANCES PERMITTED FOR USE ONLY IN SPECIAL CONCENTRATIONS

(Subject to Prescription Notification "A")

1. Acetyldihydrocodeine
2. Codeine
3. Dextropropoxyphene
4. Dihydrocodeine
5. Ethylmorphine
6. Pholcodine
7. Nalbuphine
8. Nalorphine
9. Nicocodine

10. Nicodicodeine

11. Norcodeine

12. Propiram

13. Tramadol

ADDENDUM:

1) The following are also controlled:

1.1. salts, ethers, esters, and isomers of the substances listed above, whenever their existence is possible;

1.2. salts of ethers, esters, and isomers of the substances listed above, whenever their existence is possible.

2) preparations based on acetyldihydrocodeine, codeine, dihydrocodeine, ethylmorphine, pholcodine, nicodicodeine, norcodeine, including those mixed with one or more components, in which the quantity of narcotics does not exceed 100 milligrams per dosage unit, and in which the concentration does not exceed 2.5% in preparations in indivisible forms are subject to a Special Control Prescription, in 2 (two) copies and the labeling and package insert must contain the following phrase: "SALE UNDER MEDICAL PRESCRIPTION – IT MAY ONLY BE SOLD WITH RETENTION OF THE PRESCRIPTION".

3) tramadol-based preparations, including those mixed with one or more components, in which the quantity does not exceed 100 milligrams of tramadol per dosage unit are subject to a Special Control Prescription, in 2 (two) copies, and the labeling and package insert must contain the following phrase: "SALE UNDER MEDICAL PRESCRIPTION – IT MAY ONLY BE SOLD WITH RETENTION OF THE PRESCRIPTION".

4) preparations based on dextropropoxyphene, including those mixed with one or more components, in which the quantity of narcotic does not exceed 100 milligrams per dosage unit and in which the concentration does not exceed 2.5% in indivisible preparations, are subject to a Special Control Prescription, in 2 (two) copies and the labeling and package insert must contain the following phrase: "SALE UNDER MEDICAL PRESCRIPTION – IT MAY ONLY BE SOLD WITH RETENTION OF THE PRESCRIPTION".

5) preparations based on nalbuphine, including those mixed with one or more components, in which the quantity does not exceed 10 milligrams of nalbuphine hydrochloride per dosage unit are subject to a Special Control Prescription, in 2 (two) copies, and the labeling and package insert must contain the following phrase: "SALE UNDER MEDICAL PRESCRIPTION – IT MAY ONLY BE SOLD WITH RETENTION OF THE PRESCRIPTION".

6) preparations based on propiram, including those mixed with one or more components, containing no more than 100 milligrams of propiram per dosage unit and associated with at least the same amount of methylcellulose, are subject to a Special Control Prescription, in 2 (two) copies, and the labeling and package insert must contain the following sentence: "SALE UNDER MEDICAL PRESCRIPTION – IT MAY ONLY BE SOLD WITH RETENTION OF THE PRESCRIPTION".

7) isomers listed by name in another List of this regulation are excluded from the controls related to this List.

8) the import and export of analytical standards based on the substances nalbuphine and tramadol, in which the quantity of the active ingredient subject to special control does not exceed 500 mg per unit, does not require an Import Authorization and an Export Authorization, respectively. The provisions of this addendum also apply to analytical standards based on salts, ethers, esters, and isomers, as well as salts of ethers, esters, and isomers, of the substances mentioned, unless they are explicitly excepted or included in more restricted control lists and provided that the quantity of the active ingredient subject to special control does not exceed the specified limit.

9) Isomers not listed by name and which are components of medicines granted marketing authorization by Anvisa, as well as medicines containing them, are excluded from the controls referred to in this list.

LIST – A3

LIST OF PSYCHOTROPIC SUBSTANCES

(Subject to Prescription Notification "A")

1. Amphetamine
2. Cathine
3. Chlorphentermine
4. Dexamphetamine
5. Dronabinol
6. Phenmetrazine
7. Phencyclidine
8. Fenethylamine
9. Levoamphetamine
10. Lisdexamfetamine
11. Methylphenidate
12. Methylsymprenaline
13. Amphetamine

ADDENDUM:

1) The following are also controlled:

1.1. salts, ethers, esters, and isomers of the substances listed above, whenever their existence is possible;

1.2. salts of ethers, esters, and isomers of the substances listed above, whenever their existence is possible.

2) Medicinal products granted marketing authorization by Anvisa that contain Cannabis sativa derivatives in their formulation, in a concentration of no more than 30 mg of tetrahydrocannabinol (THC) per milliliter and 30 mg of cannabidiol per milliliter, are subject to the controls referred to in this List.

3) Isomers listed by name in another List of this regulation are exempt from the controls referred to in this List.

4) The import and export of analytical standards based on the substances chlorphentermine, lisdexamfetamine, methylsynephrine and tamphetamine, in which the quantity of the active ingredient subject to special control does not exceed 500 mg per unit, do not require an Import Authorization and Export Authorization, respectively. The provisions of this addendum also apply to analytical standards based on salts, ethers, esters, and isomers, as well as salts of ethers, esters, and isomers, of the substances mentioned, unless they are explicitly excepted or included in more restricted control lists and provided that the quantity of the active ingredient subject to special control does not exceed the specified limit.

5) isomers not listed by name and which are components of medicinal products granted marketing authorization by Anvisa, as well as medicinal products containing them, are excluded from the controls related to this list.

6) the controls of this List apply to the substance dronabinol only when obtained synthetically and provided that no other components subject to special control are present, even in the form of impurities.

7) pharmaceutical inputs, in the form of plant derivatives, phytopharmaceuticals, and in bulk, based on Cannabis sativa derivatives, intended for the manufacture of Cannabis Products regularized under the terms of Collegiate Board Resolution – RDC No. 327 of 9 December 2019, are subject to the controls of this List.

8) Cannabis Products regularized under the terms of Collegiate Board Resolution – RDC No. 327 of 9 December 2019, which contain tetrahydrocannabinol (THC) above 0.2%, are subject to the controls of this List.

9) veterinary products for medicinal purposes regularized with the Ministry of Agriculture and Livestock (MAPA, in Portuguese), based on Cannabis sativa derivatives, as well as pharmaceutical inputs, in the form of plant derivatives, phytopharmaceuticals, and in bulk, based on Cannabis sativa derivatives, intended for their manufacture, are subject to the controls of this List.

LIST – B1

LIST OF PSYCHOTROPIC SUBSTANCES

(Subject to Prescription Notification "B")

1. Alphaxalone
2. Allobarbitol
3. Alprazolam

4. Amineptine
5. Amobarbital
6. Aprobarbital
7. Armodafinil
8. Barbexaclone
9. Barbital
10. Bromazepam
11. Bromazolam
12. Brotizolam
13. Butabarbital
14. Butalbital
15. Camazepam
16. Ketamine
17. Ketazolam
18. Cyclobarbital
19. Clobazam
20. Clonazepam
21. Clonazolam
22. Clorazepam
23. Clorazepate
24. Chlordiazepoxide
25. Ethyl chloride
26. methylene/dichloromethane
27. Clotiazepam
28. Cloxazolam
29. Delorazepam
30. Diazepam
31. Diclazepam
32. Esketamine
33. Estazolam
34. Eszopiclone

35. Ethchlorvynol
36. Etilamfetamine (N-ethylamphetamine)
37. Ethinamate
38. Etizolam
39. Phenazepam
40. Phenobarbital
41. Flualprazolam
42. Flubromazolam
43. Fludiazepam
44. Flunitrazepam
45. Flunitrazolam
46. Flurazepam
47. GBL
48. GHB – (gamma-hydroxybutyric acid)
49. Glutethimide
50. Halazepam
51. Haloxazolam
52. Lefetamine
53. Lemborexant
54. Ethyl loflazepate
55. Loprazolam
56. Lorazepam
57. Lormetazepam
58. Medazepam
59. Meprobamate
60. Mesocarb
61. Methylphenobarbital (prominal)
62. Methyprilone
63. Midazolam
64. Modafinil
65. Nimetazepam

66. Nitrazepam
67. Fencamfamin
68. Nordazepam
69. Oxazepam
70. Oxazolam
71. Pemoline
72. Pentazocine
73. Pentobarbital
74. Perampanel
75. Pinazepam
76. Pipradrol
77. Pyrovalerone
78. Prazepam
79. Prolintane
80. Propylhexedrine
81. Secbutabarbital
82. Secobarbital
83. Temazepam
84. Tetrazepam
85. Tiamilal
86. Thiopental
87. Triazolam
88. Trichloroethylene
89. Trihexyphenidyl
90. Vinylbital
91. Zaleplon
92. Zolpidem
93. Zopiclone

ADDENDUM:

- 1) The following are also controlled:

1.1. Salts, ethers, esters, and isomers of the substances listed above, whenever their existence is possible;

1.2. Salts of ethers, esters, and isomers of the substances listed above, whenever their existence is possible.

2) Medications containing phenobarbital, methylphenobarbital (prominal), barbital, and barbexaclone are subject to a Special Control Prescription in 2 (two) copies, and the labeling and package insert must contain the following phrase: "SALE UNDER MEDICAL PRESCRIPTION – IT MAY ONLY BE SOLD WITH RETENTION OF THE PRESCRIPTION".

3) Regarding the control of ethyl chloride:

3.1. The use of ethyl chloride for medical purposes is prohibited, as well as its use in the form of aerosol, air freshener, or in any other form that allows its improper use.

3.2. The control and inspection of the substance ethyl chloride are subject to the competent body of the Ministry of Justice and Public Security, in accordance with Law No. 10,357 of 27 December 2001, Decree No. 4,262 of 10 June 2002 and MJSP Ordinance No. 240 of 12 March 2019.

4) (Deleted)

5) (Deleted)

6) The human use of methylene chloride/dichloromethane and trichloroethylene, orally or by inhalation, is prohibited.

7) when used exclusively for legitimate industrial purposes, the substances methylene chloride/dichloromethane and trichloroethylene are excluded from the controls related to this List and are subject only to the controls imposed by List D2 of this Regulation (control of the Ministry of Justice and Public Security).

8) the prohibited isomer TH-PVP, which is listed in List "F2" of this regulation, is excluded from the controls related to this List.

9) medicines containing perampanel are subject to a Special Control Prescription, in 2 (two) copies, and the labeling and package insert must contain the following phrase: "SALE UNDER MEDICAL PRESCRIPTION – IT MAY ONLY BE SOLD WITH RETENTION OF THE PRESCRIPTION".

10) isomers listed by name in another List of this regulation are excluded from the controls related to this List.

11) the import and export of analytical standards based on the substances alphaxalone, aprobarbital, armodafinil, barbexaclone, ketamine, clorazepam, esketamine, eszopiclone, flunitrazolam, GBL, lemborexant, modafinil, perampanel, prolintane, propylhexedrine, thiamylal, thiopental, trihexyphenidyl, zaleplon, and zopiclone, in which the quantity of the active subject to special control does not exceed 500 mg per unit, does not require an Import Authorization and Export Authorization, respectively. The provisions of this addendum also apply to analytical standards based on salts, ethers, esters, and isomers, as well as salts of ethers, esters, and isomers, of the aforementioned substances, unless they are explicitly excepted or included in more restrictive control lists and provided that the quantity of the active ingredient subject to special control does not exceed the specified limit.

12) isomers not listed by name and which are components of medicinal products granted marketing authorization by Anvisa, as well as medicines containing them, are excluded from the controls related to this list.

13) Cannabis Products regularized under the terms of Collegiate Board Resolution – RDC No. 327 of 9 December 2019, which contain up to 0.2% tetrahydrocannabinol (THC), are subject to the controls of this List.

14) The dispensing and use of medicinal products containing the substances ketamine and esketamine will only be permitted in healthcare facilities.

15) The medicinal product containing the substance esketamine in spray form for nasal use must be administered in healthcare facilities under the supervision of a healthcare professional and the patient must be monitored until he/she is considered clinically stable and ready to leave the facility.

LIST – B2

LIST OF ANOREXIGENIC PSYCHOTROPIC SUBSTANCES

(Subject to Prescription Notification "B2")

1. Aminorex
2. Amfepramone
3. Fenproporex
4. Phendimetrazine
5. Phentermine
6. Mazindol
7. Mefenorex
8. Sibutramine

ADDENDUM:

1) The following are also controlled:

1.1. Salts, ethers, esters, and isomers of the substances listed above, whenever their existence is possible;

1.2. Salts of ethers, esters, and isomers of the substances listed above, whenever their existence is possible.

2) The prohibited isomer methamphetamine, which is listed in List "F2" of this regulation, is excluded from the controls related to this List.

3) The prohibited isomers 4-MEC, 5-MAPDB, and pentedrone, which are listed in List "F2" of this regulation, are exempt from the controls referred to in this List.

4) The substance DEET (N, N-diethyl-3-methylbenzamide) is exempt from the legal provisions of this Technical Regulation.

5) The isomers listed by name in another List of this regulation are exempt from the controls referred to in this List.

6) The import and export of analytical standards based on sibutramine, in which the quantity of the active ingredient subject to special control does not exceed 500 mg per unit, does not require an Import Authorization and an Export Authorization, respectively. The provisions of this addendum also apply to analytical standards based on salts, ethers, esters, and isomers, as well as salts of ethers, esters, and isomers, of the substance mentioned, unless they are explicitly excepted or included in more restricted control lists and provided that the quantity of the active ingredient subject to special control does not exceed the specified limit.

7) Isomers not listed by name and which are components of medicinal products granted marketing authorization by Anvisa, as well as medicinal products containing them, are excluded from the controls referred to in this list.

LIST – C1

LIST OF OTHER SUBSTANCES SUBJECT TO SPECIAL CONTROL

(Subject to Special Control Prescription in two copies)

1. Acepromazine
2. Valproic acid
3. Agomelatine
4. Amantadine
5. Amisulpride
6. Amitriptyline
7. Amoxapine
8. Aripiprazole
9. Asenapine
10. Atomoxetine
11. Azacyclonol
12. Beclamide
13. Benactizine
14. Benfluorex
15. Benzydamine
16. Benzoctamine
17. Benzquinamide

18. Biperiden
19. Brexpiprazole
20. Brivaracetam
21. Bupropion
22. Buspirone
23. Butaperazine
24. Butriptyline
25. Cannabidiol (CBD)
26. Captodiame
27. Carbamazepine
28. Caroxazone
29. Celecoxib
30. Cyclarbamate
31. Cyclexedrine
32. Cyclopentolate
33. Cisapride
34. Citalopram
35. Clomacran
36. Clomethiazole
37. Clomipramine
38. Chlorhexadol
39. Chlorpromazine
40. Chlorprothixene
41. Clothiapine
42. Clozapine
43. Dapoxetine
44. Desflurane
45. Desipramine
46. Desvenlafaxine
47. Deutetrabenazine
48. Dexetimide

49. Dexmedetomidine
50. Dibenzepin
51. Dimethacrine
52. Disopyramide
53. Disulfiram
54. Divalproex sodium
55. Dixyrazine
56. Donepezil
57. Doxepin
58. Droperidol
59. Duloxetine
60. Ectylurea
61. Emilcamate
62. Enflurane
63. Entacapone
64. Escitalopram
65. Etomidate
66. Etoricoxib
67. Ethosuximide
68. Phacetoperane
69. Phenprobamate
70. Phenaglycodol
71. Phenelzine
72. Pheniprazine
73. Phenytoin
74. Fluphenazine
75. Flumazenil
76. Fluoxetine
77. Flupentixol
78. Fluvoxamine
79. Gabapentin

80. Galantamine
81. Haloperidol
82. Halothane
83. Chloral hydrate
84. Hydrochlorbezetilamine
85. Hydroxydione
86. Homofenazine
87. Imicloprazine
88. Imipramine
89. Imipramine oxide
90. Iproclozide
91. Isocarboxazid
92. Isoflurane
93. Isopropyl-crotonyl-urea
94. Lacosamide
95. Lamotrigine
96. Leflunomide
97. Levetiracetam
98. Levomepromazine
99. Levomilnacipran
100. Lisuride
101. Lithium
102. Loperamide
103. Loxapine
104. Lumiracoxib
105. Lurasidone
106. Mavacantene
107. Maprotiline
108. Meclofenoxate
109. Mephenoalone
110. Mefexamide

111. Memantine
112. Mepazine
113. Mesoridazine
114. Methylaltraxone
115. Methylpentynol
116. Methysergide
117. Methixene
118. Metopromazine
119. Methoxyflurane
120. Mianserin
121. Milnacipran
122. Miltefosine
123. Minaprine
124. Mirtazapine
125. Misoprostol
126. Moclobemide
127. Molnupiravir
128. Moperone
129. Naloxone
130. Naltrexone
131. Nefazodone
132. Nialamide
133. Isobutyl nitrite
134. Isopentyl nitrite
135. Isopropyl nitrite
136. Nomifensine
137. Nortriptyline
138. Noxiptiline
139. Olanzapine
140. Opipramol
141. Oxcarbazepine

142. Oxybuprocaine (benoxinate)
143. Oxyfenamate
144. Oxypertine
145. Paliperidone
146. Parecoxib
147. Paroxetine
148. Penfluridol
149. Perphenazine
150. Pergolide
151. Periciazine (propericiazine)
152. Pimozide
153. Pipamperone
154. Pipotiazine
155. Pramipexole
156. Pregabalin
157. Primidone
158. Prochlorperazine
159. Promazine
160. Propanidine
161. Propiomazine
162. Propofol
163. Prothipendyl
164. Protriptyline
165. Proxymetacaine
166. Quetiapine
167. Ramelteon
168. Rasagiline
169. Reboxetine
170. Ribavirin
171. Rimonabant
172. Risperidone

173. Rivastigmine
174. Rofecoxib
175. Ropinirole
176. Rotigotine
177. Rufinamide
178. Selegiline
179. Sertraline
180. Sevoflurane
181. Sulpiride
182. Sultopride
183. Tacrine
184. Teriflunomide
185. Tetrabenazine
186. Tetracaine
187. Tiagabine
188. Tianeptine
189. Tiapride
190. Thioproperazine
191. Thioridazine
192. Thiothixene
193. Tolcapone
194. Topiramate
195. Tranylcypromine
196. Trazodone
197. Triclofos
198. Trifluoperazine
199. Trifluoperidol
200. Trimipramine
201. Troglitazone
202. Valdecoxib
203. Sodium valproate

- 204. Venlafaxine
- 205. Veralipride
- 206. Vigabatrin
- 207. Vilazodone
- 208. Vortioxetine
- 209. Ziprasidone
- 210. Zotepine
- 211. Zuclopenthixol

ADDENDUM:

1) The following are also controlled:

1.1. salts, ethers, esters, and isomers of the substances listed above, whenever their existence is possible;

1.2. salts of ethers, esters, and isomers of the substances listed above, whenever their existence is possible.

1.3. the provisions of items 1.1 and 1.2 do not apply to the substance cannabidiol.

2) medicinal products based on the substance loperamide are subject to SALE UNDER MEDICAL PRESCRIPTION WITHOUT RETENTION OF PRESCRIPTION.

3) the marketing and manipulation of all medicines containing loperamide or in combinations, in liquid pharmaceutical forms or in syrup for pediatric use is prohibited (SVS/MS Ordinance No. 106 of 14 September 1994 – Federal Official Gazette of 19 September 1994).

4) the purchase and use of the medicinal product containing the substance misoprostol will only be permitted in hospital establishments duly registered with the Health Authority for this purpose;

5) medicinal products based on the substance tetracaine are subject to: (a) SALE WITHOUT A MEDICAL PRESCRIPTION – in the case of pharmaceutical preparations for topical dental use, not associated with any other active ingredient; (b) SALE WITH A MEDICAL PRESCRIPTION WITHOUT RETENTION OF A PRESCRIPTION – in the case of pharmaceutical preparations for topical otorhinolaryngological use, specifically for Mouthwashes and Solutions used in the treatment of *Otitis Externa* and (c) SALE UNDER MEDICAL PRESCRIPTION WITH RETENTION OF THE PRESCRIPTION – in the case of pharmaceutical preparations for topical ophthalmological use.

6) The following substances are exempt from the legal provisions of this Technical Regulation: disulfiram, lithium (metallic and its salts) and chloral hydrate, when they are proven to be used for purposes other than medicinal formulations and are therefore not subject to the control and inspection provided for in SVS/MS Ordinances No. 344/98 and No. 6/99.

7) The following pharmaceutical forms are exempt from the legal provisions of this Technical Regulation: benzydamine-based medicinal products, whose pharmaceutical forms are: powder

for extemporaneous preparation, gynecological solution, spray, drops, mouthwash, toothpaste, and gel.

8) The use of isobutyl nitrite, isopentyl nitrite, and isopropyl nitrite for medical purposes is prohibited, as well as their use as air fresheners or in any other way that allows their improper use.

9) Isobutyl nitrite, isopentyl nitrite, and isopropyl nitrite are exempt from the legal provisions of this Technical Regulation when used exclusively for legitimate industrial purposes.

10) The substance promethazine is exempt from the legal provisions of this Technical Regulation.

11) Isomers listed by name in another List of this regulation are exempt from the controls relating to this List.

12) Isomers not listed by name and which are components of medicinal products granted marketing authorization by Anvisa, as well as medicinal products containing them, are exempt from the controls relating to this List.

13) The controls of this List apply to the substance cannabidiol only when obtained synthetically and provided that no other components subject to special control are present, even in the form of impurities.

14) the legal provisions of Collegiate Board Resolution – RDC No. 22 of 29 April 2014, or any rule that may replace it, regarding the transmission of data to the Brazilian System for the Management of Controlled Products (SNGPC, in Portuguese), medicinal products containing the substance molnupiravir that have, exclusively, temporary Emergency Use Authorization (AUE, in Portuguese). In this case, the movement and control of the medicinal product stock must be maintained only through the establishment's registration book, for the periods provided for in SVS/MS Ordinance No. 344/98 or any rule that may replace it.

LIST – C2

LIST OF RETINOIC SUBSTANCES

(Subject to Special Prescription Notification)

1. Acitretin
2. Adapalene
3. Bexarotene
4. Isotretinoin
5. Tretinoin

ADDENDUM:

1) The following are also controlled:

1.1. salts, ethers, esters, and isomers of the substances listed above, whenever their existence is possible;

1.2. salts of ethers, esters, and isomers of the substances listed above, whenever their existence is possible.

2) topical medications containing substances on this list are subject to SALE UNDER MEDICAL PRESCRIPTION WITHOUT RETENTION OF PRESCRIPTION.

3) isomers listed by name in another List of this regulation are exempt from the controls relating to this List.

4) isomers not listed by name and which are components of medicinal products granted marketing authorization by Anvisa, as well as medicinal products containing them, are exempt from the controls relating to this List.

LIST – C3

LIST OF IMMUNOSUPPRESSANT SUBSTANCES

(Subject to Special Prescription Notification)

1. Phthalimidoglutarimide (thalidomide)
2. Lenalidomide
3. Pomalidomide

ADDENDUM:

1) All salts and isomers of the substances listed above are also under control, whenever their existence is possible.

2) Isomers listed by name in another List of this regulation are excluded from the controls relating to this List.

3) Isomers not listed by name and which are components of medicinal products granted marketing authorization by Anvisa, as well as medicinal products containing them, are excluded from the controls relating to this List.

4) the control of the substances lenalidomide and pomalidomide and the medicinal products containing them must be carried out by meeting the requirements established in RDC No. 191 of 11 December 2017, or any regulation that replaces it.

LIST – C5

LIST OF ANABOLIC SUBSTANCES

(Subject to Special Control Prescription in two copies)

1. Androstanolone
2. Bolasterone
3. Boldenone

4. Chloroxomesterone
5. Clostebol
6. Dehydrochlormethyltestosterone
7. Drostanolone
8. Stanolone
9. Stanozolol
10. Ethylestrenol
11. Fluoxymesterone or fluoxymethyltestosterone
12. Formebolone
13. Gestrinone
14. Mesterolone
15. Metandienone or methandrostenolone
16. Methandranone
17. Methandriol
18. Methenolone
19. Methyltestosterone
20. Mibolerone
21. Nandrolone
22. Norethandrolone
23. Oxandrolone
24. Oxymesterone
25. Oxymetholone
26. Prasterone (dehydroepiandrosterone – DHEA)
27. Somapacitan
28. Somatogon
29. Somatropin (human growth hormone)
30. Testosterone
31. Trenbolone

ADDENDUM:

- 1) The following are also controlled:

1.1. Salts, ethers, esters, and isomers of the substances listed above, whenever their existence is possible;

1.2. Salts of ethers, esters, and isomers of the substances listed above, whenever their existence is possible.

2) Topical medications containing the substances on this list are subject to SALE UNDER MEDICAL PRESCRIPTION WITHOUT RETENTION OF PRESCRIPTION.

3) The isomers listed by name in another List of this regulation are excluded from the controls relating to this List.

4) isomers not listed by name and which are components of medicinal products granted marketing authorization by Anvisa, as well as medicinal products containing them, are exempt from the controls relating to this list.

5) the substance octyl butyl salicylate is exempt from the legal provisions of this Technical Regulation.

LIST – D1

LIST OF PRECURSOR SUBSTANCES OF NARCOTICS AND/OR PSYCHOTROPICS

(Subject to Medical Prescription without Retention)

1. 1-boc-4-AP
2. 1-boc-4-piperidone
3. 1-phenyl-2-propanone
4. 3,4-MDP-2-P ethyl glycidate (PMK ethyl glycidate); 3,4-MDP-2-P methyl glycidic acid ethyl ester
5. 3,4-MDP-2-P methyl glycidate (PMK glycidate); 3,4-MDP-2-P-methyl glycidic acid methyl ester
6. 3,4-Methylenedioxyphenyl-2-propanone
7. 4-AP (N-Phenyl-4-piperidinamine)
8. 4-piperidone
9. 3,4-MDP-2-P-methyl glycidic acid (PMK glycidic acid)
10. Anthranilic acid
11. Phenylacetic acid
12. Lysergic acid
13. N-Acetylanthranilic acid
14. P-2-P-methyl glycidic acid (BMK glycidic acid)
15. Alpha-phenylacetoacetonitrile (APAAN)
16. Alpha-phenylacetoacetamide (APAA)
17. ANPP or (1-phenethyl-N-phenylpiperidin-4-amine)

18. Dihydroergometrine
19. Dihydroergotamine
20. Ephedrine
21. Ergometrine
22. Ergotamine
23. Etaphedrine
24. Helional
25. Isosafrole
26. MAPA (methyl alpha-phenylacetoacetate)
27. Norfentanyl
28. Sassafras oil
29. Long pepper oil
30. Piperidine
31. Piperonal
32. Pseudoephedrine
33. NPP or (N-phenethyl-4-piperidinone)
34. Safrole

ADDENDUM:

- 1) all salts of the substances listed above are also controlled, whenever their existence is possible;
- 2) The following substances are also controlled: dihydroergotamine mesylate, dihydroergotamine tartrate, ergometrine maleate, ergometrine tartrate, and ergotamine tartrate.
- 3) Non-medicinal formulations containing substances on this list are exempt from the control established in SVS/MS Ordinances No. 344/98 and 6/99 when intended for other industrial segments.
- 4) Long pepper oil is obtained by extracting the leaves and thin stems of *Piper hispidinervum* C.DC., a plant native to the North of Brazil.
- 5) All optical isomers of the substance APAAN are also under control, whenever their existence is possible.
- 6) the import and export of analytical standards based on dihydroergometrine, dihydroergotamine and etaphedrine, in which the quantity of the active substance subject to special control does not exceed 500 mg per unit, does not require an Import Authorization and an Export Authorization, respectively. The provisions of this addendum also apply to analytical

standards based on the salts of the aforementioned substances, unless they are explicitly excepted or included in more restricted control lists and provided that the quantity of the active substance subject to special control does not exceed the specified limit.

7) when used exclusively for legitimate industrial purposes, the substance helional is excluded from the controls established by SVS/MS Ordinance No. 344/98.

8) the propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl esters of 3,4-MDP-2-P methyl glycidic acid are also under the control of this List.

9) methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl esters of P-2-P methyl glycidic acid are also controlled by this List.

10) oils containing safrole with an individual concentration equal to or less than 4% (four percent), when used for legitimate industrial or scientific purposes, are exempt from the establishment of an Import Quota, Import Authorization, and Export Authorization, provided for in Collegiate Board Resolution – RDC No. 659 of 30 March 2022 and its updates.

LIST – D2

LIST OF CHEMICAL INPUTS USED FOR MANUFACTURING AND SYNTHESIS OF NARCOTICS AND/OR PSYCHOTROPICS

(Subject to Control by the Ministry of Justice and Public Security)

1. Acetone
2. Hydrochloric acid
3. Sulfuric acid
4. Acetic anhydride
5. Ethyl chloride
6. Methylene chloride/dichloromethane
7. Chloroform
8. Ethyl ether
9. Methyl ethyl ketone
10. Potassium permanganate
11. Sodium sulfate
12. Toluene
13. Trichloroethylene

ADDENDUM:

1) The products and chemical inputs on this List are subject to control by the Federal Police, in accordance with Law No. 10,357 of 27 December 2001, Decree No. 4,262 of 10 June 2002, and Ordinance MJSP No. 204 of 21 October 2022, or regulations that may replace them.

2) the chemical input or substance chloroform is prohibited for use in medicinal products.

3) when the inputs on this list are used for the purpose of manufacturing products subject to health surveillance, companies must comply with specific health legislation.

LIST – E

LIST OF PROSCRIBED PLANTS AND FUNGI THAT MAY ORIGINATE NARCOTIC AND/OR PSYCHOTROPIC SUBSTANCES

1. Cannabis sativa L.
2. Claviceps paspali Stevens & Hall.
3. Datura suaveolens Willd.
4. Erythroxylum coca Lam.
5. Lophophora williamsii Coult.
6. Mitragyna speciosa
7. Papaver somniferum L.
8. Prestonia amazonica J. F. Macbr.
9. Salvia divinorum

ADDENDUM:

- 1) The import, export, trade, handling, and use of the items listed above are prohibited.
- 2) All substances obtained from the items listed above, as well as the salts, isomers, esters, and ethers of these substances, are also under control.
- 3) The plant *Lophophora williamsii* Coult. is commonly known as peyote cactus.
- 4) The import of seeds of the opium poppy (*Papaver somniferum* L.) is exempt from the control established in SVS/MS Ordinances No. 344/98 and 6/99 when it is proven that it is used for food purposes and must therefore comply with specific health legislation.
- 5) the synthetically obtained cannabidiol substance, which is listed in List "C1" of this regulation, and the synthetically obtained dronabinol substance, which is listed in List "A3" of this regulation, are exempt from the controls related to this list.
- 6) the substance papaverine, as well as the formulations containing it, are exempt from the legal provisions of this Technical Regulation, provided that they do not contain other substances subject to the special control of SVS/MS Ordinance No. 344/98.

7) the import of Cannabis-derived products by individuals is permitted for their own use, upon prescription by a legally qualified professional, for health treatment, applying the requirements established by Collegiate Board Resolution – RDC No. 660 of 30 March 2022, or any regulation that may replace it.

8) The controls relating to this list do not apply to medicinal products granted marketing authorization by Anvisa that contain Cannabis sativa derivatives in their formulation, in a concentration of no more than 30 mg of tetrahydrocannabinol (THC) per milliliter and 30 mg of cannabidiol per milliliter, provided that the requirements of this Resolution are met.

9) The controls relating to this list do not apply to isomers of substances obtained from the items listed above that are not listed by name and that are components of medicinal products granted marketing authorization by Anvisa, as well as medicinal products that contain them.

10) Cannabis Products regularized under the terms of Collegiate Board Resolution – RDC No. 327 of 9 December 2019 are excluded from the controls related to this list, which are subject to the controls established by addendums 8 of List "A3" and 13 of List "B1", as well as pharmaceutical inputs, in the form of plant derivatives, phytopharmaceuticals, and in bulk, based on Cannabis sativa derivatives, to be used in their manufacture, which are subject to the controls established by addendum 7 of List "A3".

11) veterinary products for medicinal purposes, regularized with the Ministry of Agriculture and Livestock (MAPA, in Portuguese), based on Cannabis sativa derivatives, as well as pharmaceutical inputs, in the form of plant derivatives, phytopharmaceuticals, and in bulk, based on Cannabis sativa derivatives, intended for their manufacture, are exempt from the controls related to this List, which are subject to the controls established by addendum 09 of List A3.

12) prescription by medical professionals – veterinarians, legally qualified by the Federal Council of Veterinary Medicine, for medicinal purposes, for exclusively veterinary use, of Cannabis medicines and products with Health Authorization, duly regularized for commercialization in Brazilian territory, is permitted, upon retention of a special control prescription, in accordance with the current legislation and Decree No. 5,053 of 22 April 2004.

LIST – F

LIST OF SUBSTANCES PROSCRIBED IN BRAZIL

LIST F1 – NARCOTIC SUBSTANCES

1.	2F-VIMINOL	or	2-(DISEC-BUTYLAMINO)-1-[1-[(2-FLUOROPHENYL)METHYL]PYRRHOL-2-YL]ETHANOL
2.	2-METHYL-AP-237	or	1-[2-METHYL-4-(3-PHENYL-2-PROPEN-1-YL)-1-PIPERAZINYL]-1-BUTANONE
3.	3-METHYLFENTANYL	or	N-(3-METHYL-1-(PHENETHYL-4-PIPERIDYL)PROPIONANILIDE

4.	3-METHYLTHIOFENTANYL	or	N-[3-METHYL-1-[2-(2-THYENYL)ETHYL]-4-PIPERIDYL]PROPIONANILIDE
5.	4-FLUOROISOBUTYRFENTANYL	or	N-(4-FLUOROPHENYL)-N-(1-PHENYLETHYLPIPERIDIN-4-YL)ISOBUTYRAMIDE
6.	7-HYDROXYMITRAGYNINE	or	METHYL (E)-2-[(2S,3S,7AS,12BS)-3-ETHYL-7A-HYDROXY-8-METHOXY-2,3,4,6,7,12B-HEXAHYDRO-1H-INDOLO[2,3-A]QUINOLIZIN-2-YL]-3-METHOXYPROP-2-ENOATE
7.	ACETYL-ALPHA-METYL FENTANYL	or	N-[1-(ALPHA-METHYLPHENETYL)-4-PIPERIDYL]ACETANILIDE
8.	ACETYLFENTANYL	or	N-[1-(2-PHENYLETHYL)-4-PIPERIDYL]-N-PHENYLACETAMIDE
9.	ACETORPHINE	or	3-O-ACETYLTETRAHYDRO-7-ALPHA-(1-HYDROXY-1-METHYLBUTYL)-6,14-ENDOETHENE-ORIPAVIN
10.	ACRYLOYLFENTANYL	or	N N-PHENYL-N-[1-(2-PHENYLETHYL)PIPERIDIN-4-YL]PROP-2-ENAMIDE
11.	AH-7921	or	3,4-DICHLORO-N-{{1-(DIMETHYLAMINO)CYCLOHEXYL METHYL}BENZAMIDE
12.	ALPHA-METHYL FENTANYL	or	N-[1-(ALPHA-METHYLPHENETYL)-4-PIPERIDYL]PROPIONANILIDE
13.	ALPHA-METHYLTHIOFENTANYL	or	N-[1-[1-METHYL-2-(2-THIENYL)ETHYL]-4-PIPERIDYL]PROPIONANILIDE
14.	BETA-HYDROXY-3-METHYL FENTANYL	or	N-[1-(BETA-HYDROXYPHENETYL)-3-METHYL-4-PIPERIDYL]PROPIONANILIDE
15.	BETA-HYDROXYFENTANYL	or	N-[1-(BETA-HYDROXYPHENETYL)-4-PIPERIDYL]PROPIONANILIDE
16.	BRORPHINE	or	1-[1-[1-(4-BROMOPHENYL)ETHYL]-PIPERIDIN-4-YL]-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE
17.	BUTYRFENTANYL	or	BUTYRYL FENTANIL; N-(1-PHENETYLP IPERIDIN-4-YL)-N-PHENYLBUTYRAMIDE
18.	BUTONITAZENE	or	2-[2-[(4-BUTOXYPHENYL)METHYL]-5-NITROBENZIMIDAZOL-1-YL]-N, N – DITHYLETHANAMINE

19.	CARFENTANIL	or	4-CARBOMETHOXYPHENTANYL; METHYL-PHENYLETHYL-4-(N-PHENYLPROPIONAMIDE)PIPERIDINE-4-CARBOXYLATE
20.	KETOBEMIDONE	or	4-META-HYDROXYPHENYL-1-METHYL-4-PROPIONYLPYPERIDINE
21.	CYCLOPROPYLFENTANYL	or	N-PHENYL-N-[1-(2-PHENYLETHYL)PIPERIDIN-4-YL]CYCLOPROPANECARBOXAMIDE
22.	COCAINE	or	BENZOYLECGONINE METHYL ESTER
23.	CROTONYLFENTANYL	or	(2E)-N-PHENYL-N-[1-(2-PHENYLETHYL)PIPERIDIN-4-YL]BUT-2-ENAMIDE
24.	DESOMORPHINE	or	DIHYDRODEOXYMORPHINE
25.	DIHYDROETORPHINE	or	7,8-DIHYDRO-7-ALPHA-[1-(R)-HYDROXY-1-METHYLBUTYL]-6,14-ENDO-ETHANETRAHYDROORIPAVINE
26.	ECGONINE	or	(-)-3-HYDROXITROPANE-2-CARBOXYLATE
27.	ETAZENE	or	2-[(4-ETHOXYPHENYL)METHYL]-N,N-DIETHYL-1H-BENZIMIDAZOLE-1-ETHANAMINE
28.	ETONITAZEPINE	or	2-[(4-ETOXYPHENYL)METHYL]-5-NITRO-1-(2-PYRROLIDIN-1-YLETHYL)-1-H-BENZOIMIDAZOLE
29.	ETORPHINE	or	TETRAHYDRO-7-ALPHA-(1-HYDROXY-1-METHYLBUTYL)-6,14-ENDOETHENE-ORIPAVIN
30.	FURANYLFENTANYL	or	N-(1-PHENYLETHYLPYPERIDIN-4-YL)-N-PHENYLPURAN-2-CARBOXAMIDE
31.	HEROIN	or	DIACETYLMORPHINE
32.	ISOTONITAZENE	or	N,N-DIETHYL-2-(2-(4-ISOPROPOXYBENZYL)-5-NITRO-1HBENZO[D]IMIDAZOLE-1-YL)ETAN-1-AMINE
33.	MDPV	or	1-(1,3-BENZODIOXOL-5-IL)-2-(PYRROLIDIN-1-IL)-1-PENTANONE
34.	METONITAZENE	or	N,N-DIETHYL-2-{2-[(4-METHOXYPHENYL)METHYL]-5-NITRO-1HBENZIMIDAZOL-1-YL}ETAN-1-AMINE

35.	METHOXYACETYLFENTANYL	or	2-METHOXY-N-PHENYL-N-[1-(2-PHENYLETHYL)-4-PIPERIDINYL]ACETAMIDE
36.	MITRAGYNINE	or	METHYL (E)-2-[(2S,3S,12BS)-3-ETHYL-8-METHOXY-1,2,3,4,6,7,12,12B-OCTAHYDROINDOLO[2,3-A]QUINOLIZIN-2-YL]-3-METHOXYPROP-2-ENOATE
37.	MPPP	or	PIPERIDINE 1-METHYL-4-PHENYL-4-PROPIONATE (ESTER)
38.	MT-45	or	1-CYCLOHEXYL-4-(1,2-DIPHENYLETHYL)PIPERAZINE
39.	N-DESETHYL ETONITAZENE	or	2-[2-[(4-ethoxyphenyl)methyl]-5-nitrobenzimidazol-1-yl]-N-ethylethanamine
40.	N,N-DIMETHYLAMINO ETONITAZENE	or	2-[2-(4-ethoxybenzyl)-5-nitro-1H-benzimidazol-1-yl]-N,N-dimethylethylamine
41.	N-PYRROLIDINE METONITAZENE	or	2-[(4-methoxyphenyl)methyl]-5-nitro-1-(2-pyrrolidin-1-ylethyl)benzimidazole
42.	OCFENTANYL	or	N-(2-FLUOROPHENYL)-2-METHOXY-N-[1-(2-PHENYLETHYL)PIPERIDIN-4-YL]ACETAMIDE
43.	ORTHO-FLUOROFENTANYL	or	2-FLUOROFENTANYL; N-(2-FLUOROPHENYL)-N-[1-(2-PHENYLETHYL)-4-PIPERIDINYL]PROPANAMIDE
44.	PARA-FLUOROBUTYRYLFENTANYL	or	4-FLUOROBUTYRYLFENTANYL; 4F-BF; N-(4-FLUOROPHENYL)-N-[1-(2-PHENYLETHYL)PIPERIDIN-4-YL] BUTANAMIDE)
45.	PARA-FLUOROFENTANYL	or	4'-FLUORO-N-(1-PHENETHYL-4-PIPERIDYL)PROPIONANILIDE
46.	PEPAP	or	PIPERIDINE 1-PHENETHYL-4-PHENYL-4-ACETATE (ESTER)
47.	PROTONITAZENE	or	N,N-DIETHYL-5-NITRO-2-[(4-PROPOXYPHENYL)METHYL]-1H-BENZIMIDAZOLE-1-ETHANAMINE
48.	TETRAHYDROFURANYLPHEENTANYL	or	N-(1-PHENYLETHYLPIPERIDIN-4-YL)-N-PHENYLTETRAHYDROFURAN-2-CARBOXAMIDE
49.	THIOFENTANYL	or	N-[1-[2-(THIENYL)ETHYL]-4-PIPERIDYL]PROPIONANILIDE

50.	U-47700	or	3,4-DICHLORO-N-((1S,2S)-2-(DIMETHYLAMINO)CYCLOHEXYL)-N-METHYLBENZAMIDE
51.	VALERILFENTANYL	or	N-PHENYL-N-[1-(2-PHENYLETHYL)PIPERIDIN-4-IL]PENTANAMIDE

ADDENDUM:

1) The following are also controlled:

1.1. Salts, ethers, esters, and isomers of the substances listed above, whenever their existence is possible;

1.2. Salts of ethers, esters, and isomers of the substances listed above, whenever their existence is possible.

1.3. All esters and derivatives of the substance ecgonine that can be converted into ecgonine and cocaine.

2) The isomers listed by name in another List of this regulation are exempt from the controls related to this List.

3) The veterinary use of the substances carfentanyl and etorphine is excluded from the prohibition, provided that it is duly authorized by the Ministry of Agriculture, Livestock and Food Supply and that the other control requirements established by current legislation are met.

4) isomers not listed by name and which are components of medicinal products granted marketing authorization by Anvisa, as well as medicinal products that contain them, are excluded from the controls relating to this list.

LIST F2 – PSYCHOTROPIC SUBSTANCES

a) SUBSTANCES

1.	(+) – LYSERGIDE	or	LSD; LSD-25; 9,10-DIDEHYDRO-N,N-DIETHYL-6-METHYLERGOLINE-8BETA-CARBOXAMIDE
2.	1B-LSD	or	1-BUTYRYL-LSD; N-BUTYRYL-LYSERGIC ACID DIETHYLAMIDE; (6AR,9R)-4-BUTANOYL-N,N-DIETHYL-7-METHYL-6,6A,8,9-TETRAHYDROINDOLO[4,3-FG]QUINOLINE-9-CARBOXAMIDE
3.	1cP-LSD	or	1-CYCLOPROPIONYL LSD; N1-(CYCLOPROPYLMETHANOYL)-LYSERGIC ACID DIETHYLAMIDE; (6AR,9R)-4-

			(CYCLOPROPANECARBONYL)-N,N-DIETHYL-7-METHYL-6,6A,8,9-TETRAHYDROINDOLO[4,3-FG]QUINOLINE-9-CARBOXAMIDE
4.	1P-LSD	or	1-PROPIONYL-LSD; PROPIONYL-LYSERGIC ACID 1-DIETHYLAMIDE; (6AR,9R)-N,N-DIETHYL-7-METHYL-4-PROPANOYL-6,6A,8,9-TETRAHYDROINDOLO[4,3-FG]QUINOLINE-9-CARBOXAMIDE
5.	2C-B	or	4-BROMO-2,5-DIMETHOXYPHENYLETHYLAMINE
6.	2C-C	or	4-CHLORO-2,5-DIMETHOXYPHENYLETHYLAMINE
7.	2C-D	or	4-METHYL-2,5-DIMETHOXYPHENYLETHYLAMINE
8.	2C-E	or	4-ETHYL-2,5-DIMETHOXYPHENYLETHYLAMINE
9.	2C-F	or	4-FLUORO-2,5-DIMETHOXYPHENYLETHYLAMINE
10.	2C-I	or	4-iodo-2,5-DIMETHOXYPHENYLETHYLAMINE
11.	2C-T-2	or	4-ETHYL-THIO-2,5-DIMETHOXYPHENYLETHYLAMINE
12.	2C-T-7	or	2,5-DIMETHOXY-4-PROPYLTIOPHENYLETHYLAMINE (2C-T-7)
13.	2-MeO- DIPHENIDINE	or	1-(1-(2-METHOXYPHENIL)-2-PHENYLETHYL)PIPERIDINE; MXP; METHOXYPHENIDINE
14.	2-FLUORODESCHLOROKETAMINE	or	2-(2-FLUOROPHENYL)-2-(METHYLAMINO)CYCLOHEXAN-1-ONE
15.	3- CHLOROMETCATINONE	or	3-CMC; 1-(3-CHLOROPHENYL)-2-(METHYLAMINO)PROPAN-1-ONE
16.	3- FLUOROPHENMETRAZINE	or	2-(3-FLUOROPHENYL)-3-METHYLMORPHOLINE; 3-HPM
17.	3-MeO-PCP	or	3-METHOXYPHENCYCLIDINE; 1-[1-(3-METHOXYPHENIL)CYCLOHEXYL]PIPERIDINE
18.	3-MMC	or	3-METHYLMETCATHINONE; 2-(METHYLAMINO)-1-(3-METHYLPHENYL)-1-PROPANONE
19.	4-AcO-DMT	or	4-ACETOXY-N,N-DIMETHYLTRIPTAMINE
20.	4-AcO-MET	or	4-ACETOXY-N-METHYL-N-ETHYLTRIPTAMINE

21.	4- BROMOMETHATINONE	or	4-BMC; BREFEDRONE; 1-(4-BROMOPHENYL)-2-(METHYLAMINO)PROPAN-1-ONE
22.	4-Cl-ALPHA-PVP	or	1-(4-CHLOROPHENYL)-2-(PYRROLIDIN-1-YL)PENTAN-1-ONE
23.	4- CHLOROMETHATINONE	or	CLEPHEDRONE; 4-CMC; 1-(4-CHLOROPHENYL)-2-(METHYLAMINO)PROPAN-1-ONE
24.	4-FA	or	4-FLUOROAMPHETAMINE; 1-(4-FLUOROPHENYL)PROPAN-2-AMINE
25.	4- FLUOROMETCATINONE	or	FLEPHEDRONE; 4-FMC; 1-(4-FLUOROPHENYL)-2-(METHYLAMINO)PROPAN-1-ONE
26.	4-F-MDMB-BINACA	or	4F-MDMB-BUTINACA; METHYL 2-{{1-(4-FLUOROBUTYL)-1H-INDAZOLE-3-CARBONYL}AMINO}-3,3-DIMETHYLBUTANOATE
27.	4-HO-MIPT	or	3-{2-[METHYL(PROPAN-2-YL)AMINO]ETHYL}-1H-INDOL-4-OL; 4-HYDROXY-N-ISOPROPYL-N-METHYLTRYPTAMINE
28.	4-MEAPP	or	2-(ETHYLAMINO)-1-(4-METHYLPHENYL)-1-PENTANONE; 4-METHYL-ALPHA-ETHYLAMINOPENTIOPHENONE; N-ETHYL-4'-METHYLNORPENTEDRONE
29.	4-MEC	or	4- METHYLETHYLCATHINONE; 2-(ETHYLAMINE)-1-(4-METHYLPHENYL)-PROPAN-1-ONE
30.	4- METHYLAMINOREX	or	(±)-CIS-2-AMINO-4-METHYL-5-PHENYL-2-OXAZOLINE
31.	4-MTA	or	4- METHYLTIOAMPHETAMINE
32.	4,4'- DMAR	or	4,4'-DIMETHYLAMINOREX; 4-METHYL-5-(4-METHYLPHENYL)-4,5-DIHYDRO-1,3-OXAZOL-2-AMINE
33.	5-APB	or	1-(BENZOFURAN-5-YL)PROPAN-2-AMINE
34.	5-APDB	or	1-(2,3-DIHYDROBENZOFURAN-5-YL)PROPAN-2-AMINE
35.	5C-MDA-19	or	BZO-POXIZID; PENTIL MDA-19; (2Z)-2-(1,2-DIHYDRO-2-OXO-1-PENTYL-3H-INDOL-3-YLIDENE)BENZOIC ACID HYDRAZIDE
36.	5-EAPB	or	1-(BENZOFURAN-5-YL)-N-ETHYLPROPAN-2-AMINE

37.	5F-AB-PFUPPYCA	or	5F-3,5-AB-PFUPPYCA; N-(1-AMINO-3-METHYL-1-OXOBUTAN-2-YL)-1-(5-FLUOROPENTYL)-3-(4-FLUOROPHENYL)-1H-PYRAZOLE-5-CARBOXAMIDE
38.	5F-ADB	or	METHYL-S-2-[1-(5-FLUOROPENTYL)-1H-INDAZOLE-3-CARBOXAMIDO]-3,3-DIMETHYLBUTANOATE
39.	5F-AKB48	or	5F-APINACA; N-(1-ADAMANTYL)-1-(5-FLUOROPENTYL)INDAZOLE-3-CARBOXAMIDE
40.	5F-AMB-PINACA	or	5F-AMB; 5F-MMB-PINACA; METHYL 2-{{1-(5-FLUOROPENTYL)-1H-INDAZOLE-3-CARBONYL}AMINO}-3- METHYLBUTANOATE
41.	5F-MDA-19	or	5-FLUORO BZO-POXIZID; 5-FLUOROPENTYL MDA-19; (Z)-N'-(1-(5-FLUOROPENTYL)-2-OXOINDOLIN-3-YLIDENE)BENZOHYDRAZIDE
42.	5F-MDMB-PICA	or	5F-MDMB-2201; METHYL 2-{{1-(5-FLUOROPENTYL)-1HINDOL-3-CARBONYL}AMINO}-3,3-DIMETHYLBUTANOATE
43.	5F-PB-22	or	QUINOLIN-8-YL 1-(5-FLUOROPENTYL)-1H-INDOL-3-CARBOXYLATE
44.	5-IAI	or	2,3-DIHYDRO-5-iodo-1H-INDENE-2-AMINE
45.	5-MAPDB	or	1-(2,3-DIHYDROBENZOFURAN-5-YL)-N-METHYLPROPAN-2-AMINE
46.	5-MeO-AMT	or	5-METHOXY-ALPHA-METHYLTRYPTAMINE
47.	5-MeO-DALT	or	N-[2-(5-METHOXY-1H-INDOL-3-YL)ETHYL]-N-(PROP-2-EN-1-IL)PROP-2-EN-1-AMINE; 5-METHOXY-N,N-DIALYLTRYPTAMINE
48.	5-MeO-DIPT	or	5-METHOXY-N,N-DIISOPROPYLTRYPTAMINE
49.	5-MeO-DMT	or	5-METHOXY-N,N-DIMETHYLTRYPTAMINE
50.	5-MeO-MIPT	or	5-METHOXY-N,N-METHYL ISOPROPYLTRYPTAMINE
51.	25B-NBOH	or	2-{{2-(4-BROMO-2,5-DIMETHOXYPHENYL)ETHYL}AMINO}METHYL)PHENOL
52.	25B-NBOMe	or	2-(4-BROMO-2,5-DIMETHOXY-PHENYL)-N-{{2-METHOXYPHENYL}METHYL}ETHANOAMINE

53.	25C-NBF	or	2-(4-CHLORO-2,5-DIMETHOXYPHENYL)-N-(2-FLUOROBENZYL)ETHANAMINE
54.	25C-NBOH	or	2-({[2-(4-CHLORO-2,5-DIMETHOXYPHENYL)ETHYL]AMINO}METHYL)PHENOL
55.	25C-NBOMe	or	2-(4-CHLORO-2,5-DIMETHOXY-PHENYL)-N-[(2-METHOXYPHENYL)METHYL]ETHANOAMINE
56.	25D-NBOMe	or	2-(4-METHYL-2,5-DIMETHOXY-PHENYL)-N-[(2-METHOXYPHENYL)METHYL]ETHANOAMINE
57.	25E-NBOH	or	2-({[2-(4-ETHYL-2,5-DIMETHOXYPHENYL)ETHYL]AMINO}METHYL)PHENOL
58.	25E-NBOMe	or	2-(4-ETHYL-2,5-DIMETHOXY-PHENYL)-N-[(2-METHOXYPHENYL)METHYL]ETHANOAMINE
59.	25H-NBOH	or	2-({[2,5-DIMETHOXYPHENYL)ETHYL]AMINO}METHYL)PHENOL
60.	25H-NBOMe	or	2-(2,5-DIMETHOXY-PHENYL)-N-[(2-METHOXYPHENYL)METHYL]ETHANOAMINE
61.	25I-NBF	or	CIMBI-21; 2C-I-NBF; N-(2-FLUOROBENZYL)-2-(4-IODO-2,5-DIMETHOXYPHENYL)ETHAN-1-AMINE
62.	25I-NBOH	or	2CI-NBOH; 2-({[2-(4-IODO-2,5-DIMETHOXYPHENYL)ETHYL]AMINO}METHYL)PHENOL
63.	25I-NBOMe	or	2-(4-IODO-2,5-DIMETHOXY-PHENYL)-N-[(2-METHOXYPHENYL)METHYL]ETHANOAMINE
64.	25N-NBOMe	or	2-(4-NITRO-2,5-DIMETHOXY-PHENYL)-N-[(2-METHOXYPHENYL)METHYL]ETHANOAMINE
65.	25P-NBOMe	or	2-(4-PROPYL-2,5-DIMETHOXY-PHENYL)-N-[(2-METHOXYPHENYL)METHYL]ETHANOAMINE
66.	25T2-NBOMe	or	2-(4-THIOETHYL-2,5-DIMETHOXY-PHENYL)-N-[(2-METHOXYPHENYL)METHYL]ETHANOAMINE
67.	25T4-NBOMe	or	2-[4-(1-METHYL-THIOTHYL)-2,5-DIMETHOXY-PHENYL]-N-[(2-METHOXYPHENYL)METHYL]ETHANOAMINE
68.	25T7-NBOMe	or	2-(4-THIOPROPYL-2,5-DIMETHOXY-PHENYL)-N-[(2-METHOXYPHENYL)METHYL]ETHANOAMINE

69.	30C-NBOMe	or	C30-NBOME; 2-(4-CHLORO-2,5-DIMETHOXYPHENYL)-N-(3,4,5-TRIMETHOXYBENZYL)ETAN-1-AMINE
70.	AB-CHMINACA	or	N-(1-AMINO-3-METHYL-1-OXOBUTAN-2-YL)-1-(CYCLOHEXYLMETHYL)-1H-INDAZOLE-3-CARBOXAMIDE
71.	AB-FUBINACA	or	N-[1-AMINO-3-METHYL-1-OXOBUTAN-2-YL]-1-[(4-FLUOROPHENYL)METHYL]-1H-INDAZOLE-3-CARBOXAMIDE
72.	AB-PINACA	or	N-[(2S)-1-AMINO-3-METHYL-1-OXOBUTAN-2-YL]-1-PENTYL-1H-INDAZOLE-3-CARBOXAMIDE
73.	ADB-5Br-INACA	or	(S)-N-(1-AMINO-3,3-DIMETHYL-1-OXOBUTAN-2-IL)-5-BROMO-1H-INDAZOLE-3-CARBOXAMIDE
74.	ADB-BUTINACA	or	N-[1-(AMINOCARBONYL)-2,2-DIMETHYLPROPYL]-1-BUTYL-1H-INDAZOLE-3-CARBOXAMIDE
75.	ADB-CHMINACA	or	MAB-CHMINACA; N-(1-AMINO-3,3-DIMETHYL-1-OXOBUTAN-2-YL)-1-(CYCLOHEXYLMETHYL)-1H-INDAZOLE-3-CARBOXAMIDE
76.	ADB-FUBIATA	or	AD-18; FUB-ACADB; 2-[[2-[1-[(4-FLUOROPHENYL)METHYL]INDOL-3-YL]ACETYL]AMINO]-3,3-DIMETHYL-BUTANAMIDE
77.	ADB-FUBINACA	or	N-(1-AMINO-3,3-DIMETHYL-1-OXOBUTAN-2-YL)-1-(4-FLUOROBENZYL)-1H-INDAZOLE-3-CARBOXAMIDE
78.	ADB-INACA	or	N-[(1S)-1-(AMINOCARBONYL)-2,2-DIMETHYLPROPYL]-1H-INDAZOLE-3-CARBOXAMIDE
79.	ALD-52	or	1-ACETYL-LSD; 1-ACETYL-LYSERGIC ACID DIETHYLAMIDE; (6AR,9R)-4-ACETYL-N,N-DIETHYL-7-METHYL-6,6A,8,9-TETRAHYDROINDOLO[4,3-FG]QUINOLINE-9-CARBOXAMIDE
80.	ALPHA-D2PV	or	1,2-DIPHENYL-2-(PYRROLIDIN-1-YL)ETAN-1-ONE
81.	ALPHA-EAPP	or	ALPHA-ETHYLAMINOPENTIOPHENONE; 2-(ETHYLAMINO)-1-PHENYLPENTAN-1-ONE
82.	ALPHA-PHP	or	1-PHENYL-2-(PYRROLIDIN-1-YL)HEXAN-1-ONE

83.	ALPHA-PIHP	or	ALPHA-PYRROLIDINOISOHEZANOPHENONE; 4-METHYL-1-PHENYL-2-(PYRROLIDIN-1-YL)PENTAN-1-ONE
84.	ALPHA-PVP	or	1-PHENYL-2-(PYRROLIDIN-1-YL)PENTAN-1-ONE
85.	AKB48	or	APINACA; N-ADAMANTYL-1-PENTYLYNDAZOLE-3-CARBOXAMIDE
86.	AM-2201	or	(1-(5-FLUOROPENTYL)-1H-INDOL-3-IL)-1-NAPHTHALENYL- METHANONE
87.	AMT	or	ALPHA-METHYLTRYPTAMINE
88.	BENZOPHETAMINE	or	N-BENZYL-N, ALPHA-DIMETHYLPHENETYLAMINE
89.	BETACETO-DMBDB	or	DIBUTYLONE; METHYLBUTYLONE; BK-DMBDB; BK-MMBDB; 1-BENZO[D] [1,3]DIOXOL-5-IL)-2-(DIMETHYLAMINO)BUTAN-1-ONE
90.	BROLANPHETAMINE	or	DOB; (±)-4-BROMO-2,5-DIMETHOXY-ALPHA-METHYLPHENETYLAMINE
91.	BZO-4en-POXIZID	or	(Z)-N'-(2-OXO-1-(PENT-4-EN-1-IL)INDOLIN-3-YLIDENE)BENZOHYDRAZIDE
92.	BZO-CHMOXIZID	or	(Z)-N'-(1-(CYCLOHEXYLMETYL)-2-OXOINDOLIN-3-YLIDENE)BENZOHYDRAZIDE
93.	BZO-HEPOXIZID	or	(Z)-N'-(1- HEPTYL-2- OXOINDOLIN-3- ILIDENE)BENZO HYDRAZIDE
94.	BZP	or	1- BENZYLPIPERAZINE
95.	CATINONE	or	(-)-(S)-2- AMINOPROPIOPHENONE
96.	CH-PIATA	or	N-CYCLOHEXYL-2-(1-PENTYL-1H-INDOL-3-YL)ACETAMIDE
97.	CLOBENZOREX	or	N-[(2-CHLOROPHENYL)METHYL]-1-PHENYLPROPAN-2-AMINE
98.	CUMYL-4-CN-BINACA	or	SGT-78; 4-CN-CUMYL-BINACA; CUMYL-CB-PINACA; CUMYL-CYBINACA; 4-CYANO CUMYL-BUTINAC; 1-(4-CYANOBUTYL)-N-(1-METHYL-1-PHENYLETHYL)-1H-INDAZOLE-3- CARBOXAMIDE

99.	CUMYL-PEGACLONE	or	5-PENTYL-2-(2-PHENYLPROPAN-2-YL)-2,5-DIHYDRO-1H-PYRIDINE[4,3-B]INDOL-1-ONE
100.	DET	or	3-[2-(DIETHYLAMINO)ETHYL]INDOL
101.	DIPHENIDINE	or	1-(1,2-DIPHENYLETHYL)PIPERIDINE; DEP
102.	DIIDRO-LSD	or	(8B)-N,N-DIETHYL-6-METHYL-9,10-DIDEHYDRO-2,3-DIHYDROERGOLINE-8-CARBOXAMIDE
103.	DIMETHYLONE	or	BK-MDDMA; BK-DMBDP; 1-(BENZO[D][1,3]DIOXOL-5-IL)-2-(DIMETHYLAMINO)PROPAN-1-ONE
104.	DIPENTYLONE	or	1-(1,3-BENZODIOXOL-5-YL)-2-(DIMETHYLAMINO)PENTAN-1-ONE
105.	DMA	or	(±)-2,5-DIMETHOXY-ALPHA-METHYLPHENETYLAMINE
106.	DMAA	or	1,3-DIMETHYLAMYLAMINE; 4-METHYLHEXAN-2-AMINE
107.	DMBA	or	1,3-DIMETHYLBUTYLAMINE; 4-METHYLPENTAN-2-AMINE
108.	DMHP	or	3-(1,2-DIMETHYLHEPTYL)-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO[B,D]PYRANE-1-OL
109.	DMT	or	3-[2-(DIMETHYLAMINO)ETHYL] INDOL ; N,N-DIMETHYLTRIPTAMINE
110.	DOC	or	4-CHLORO-2,5-DIMETHOXYAMPHETAMINE
111.	DOET	or	(±)-4-ETHYL-2,5-DIMETHOXY-ALPHA-METHYLPHENETYLAMINE
112.	DOI	or	4-IODO-2,5-DIMETHOXYAMPHETAMINE
113.	EAM-2201	or	(1-(5-FLUOROPENTYL)-1H-INDOL-3-YL)-(4-ETHYL-1-NAPHTHALENYL)-METHANONE
114.	ERGINE	or	LSA (D-LYSERGIC ACID AMIDE)
115.	ETHYCYCLIDINE	or	PCE ; N-ETHYL-1-PHENYLCYCLOHEXYLAMINE
116.	ETHYLPHENIDATE	or	ETHYL-2-PHENYL-2-(PIPERIDIN-2-YL) ACETATE
117.	ETHYLONE	or	BK-MDEA; MDEC; 1-(1,3-BENZODIOXOL-5-IL)-2-(ETHYLAMINO)-1-PROPANONE

118.	ETRYPTAMINE	or	3-(2-AMINOBTYL)INDOL
119.	EUTHYLONE	or	1-(1,3-BENZODIOXOL-5-YL)-2-(ETHYLAMINO)BUTAN-1-ONE
120.	FUB-AMB	or	AMB-FUBINACA; MMB-FUBINACA; METHYL (2S)-2-[[1-[(4-FLUOROPHENYL)METHYL]INDAZOLE-3-CARBONYL]AMINO]-3- METHYLBUTANOATE
121.	ISOPROPYLBENZYLAMINE	or	N-BENZYLPROPAN-2-AMINE
122.	JWH-018	or	1-NAPHTHALENYL-(1-PENTYL-1H-INDOL-3-YL)-METHANONE
123.	JWH-071	or	(1-ETHYL-1H-INDOL-3-YL)-1-NAPHTHALENYL-METHANONE
124.	JWH-072	or	(1-PROPYLINDOL-3-YL)NAPHTHALEN-1-YL-METHANONE
125.	JWH-073	or	NAPHTALEN-1-IL(1-BUTYLYNDOL-3-IL) METHANONE
126.	JWH-081	or	4-METHOXINAPHTHALEN-1-YL-(1-PENTYLYNDOL-3-YL)METHANONE
127.	JWH-098	or	(4-METHOXY1-NAPHTHALENYL)(2-METHYL-1-PENTYL-1H-INDOL-3-YL) METHANONE
128.	JWH-122	or	4-METHYLNAPHTHALEN-1-IL-(1-PENTYLYNDOL-3-YL) METHANONE
129.	JWH-210	or	4-ETHYLNAPHTHALEN-1-IL-(1-PENTYLYNDOL-3-YL) METHANONE
130.	JWH-250	or	2-(2-METHOXYPHENYL)-1-(1-PENTYL-1-INDOL-3-YL) ETHANONE
131.	JWH-251	or	2-(2-METHYLPHENYL)-1-(1-PENTYL-1H-INDOL-3-YL) ETHANONE
132.	JWH-252	or	1-(2-METHYL-1-PENTYLYNDOL-3-YL)-2-(2-METHYLPHENYL) ETHANONE
133.	JWH-253	or	1-(2-METHYL-1-PENTYL-1H-INDOL-3-YL)-2-(3-METHOXY-PHENYL) ETHANONE
134.	LEVOMETHAMPHETAMINE	or	L- METHAMPHETAMINE

135.	MAM-2201	or	(1-(5-FLUOROPENTYL)-1H-INDOL-3-YL)(4-METHYL-1-NAPHTHALENYL)-METHANONE
136.	MAM-2201 N-(4-HYDROXIPENTYL)	or	[1-(5-FLUORO-4-HYDROXIPENTYL)-1H-INDOL-3-YL](4-METHYL-1-NAPHTHALENYL)METHANONE
137.	MAM-2201 N-(5-CHLOROPENTYL)	or	[1-(5-CHLOROPENTYL)-1H-INDOL-3-YL](4-METHYL-1-NAPHTHALENYL)METHANONE
138.	MDMB-4EN-PINACA	or	(S)-3,3-DIMETHYL-2-(1-(PENT-4-EN-1-IL)-1HINDAZOLE-3-CARBOXAMIDO)BUTANOATE
139.	MDMB-5Br-INACA	or	METHYL(S)-2-(5-BROMO-1H-INDAZOLE-3-CARBOXAMIDO)-3,3-DIMETHYLBUTANOATE
140.	MDMB-INACA	or	2-(1H-INDAZOLE-3-CARBONYLAMINO)-3,3-METHYLDIMETHYL-BUTANOATE
141.	mCPP	or	1-(3-CHLOROPHENYL)PIPERAZINE
142.	MDA-19	or	BZO-HEXOXIZID; N'-(1-HEXYL-2-OXOINDOLIN-3-YLIDENE)BENZOHYDRAZIDE; N-(1-HEXYL-2-HYDROXIINDOL-3-YL)IMINOBENZAMIDE
143.	MDAI	or	5,6-METHYLENEDIOXY-2-AMINOINDAN
144.	MDE	or	MDEA; N-ETHYL MDA; (±)-N-ETHYL-ALPHA-METHYL-3,4-(METHYLENEDIOXY)PHENETYLAMINE
145.	MDMA	or	(±)-N,ALPHA-DIMETHYL-3,4-(METHYLENEDIOXY)PHENETYLAMINE; 3,4-METHYLENEDIOXYMETHAMPHETAMINE
146.	MECLOQUALONE	or	3-(O-CHLOROPHENYL)-2-METHYL-4(3H)-QUINAZOLINONE
147.	MEPHEDRONE	or	2-METHYLAMINO-1-(4-METHYLPHENYL)-PROPAN-1-ONE
148.	MESCALINE	or	3,4,5-TRIMETHOXYPHENETYLAMINE
148.	METALLYLESKALINE	or	2-[3,5-DIMETHOXY-4-(2-METHYLPROP-2-ENOXY)PHENYL]ETHANAMINE
150.	METHAMPHETAMINE		
151.	METAQUALONE	ou	2-METHYL-3-O-TOLYL-4(3H)-QUINAZOLINONE

152.	METCATINONE	or	2-(METHYLAMINO)-1-PHENYLPROPAN-1-ONE
153.	METHYLONE	or	BK-MDMA; MDMC; 1-(1,3-BENZODIOXOL-5-IL)-2-(METHYLAMINO)-1-PROPANONE
154.	METHIOPROPAMINE	or	N-METHYL-1-THIOPHEN-2-YLPROPAN-2-AMINE
155.	MMDA	or	5-METHOXY-ALPHA-METHYL-3,4-(METHYLENEDIOXY)PHENETYLAMINE
156.	MXE	or	METHOXETAMINE; 2-(ETHYLAMINO)-2-(3-METHOXYPHENYL)-CYCLOHEXANONE
157.	N-ACETYL-3,4-MDMC	or	N-ACETYL-3,4-METHYLENEDIOXYMETHCATHINONE; N-ACETYLMETTYLONE; N-[2-(1,3-BENZODIOXOL-5-IL)-1-METHYL-2-OXOETHYL]-N-METHYL-ACETAMIDE
158.	N-ETHYLCATHINONE	or	2-(ETHYLAMINE)-1-PHENYLPROPAN-1-ONE
159.	N-ETHYLHEXEDRONE	or	2-(ETHYLAMINO)-1-PHENYLHEXAN-1-ONE; HEXEN; NEH
160.	N-ETHYLPENTILONE	or	EPHILONE; N-ETHYLNORPENTYLONE; 1-(2H-1,3-BENZODIOXOL-5-YL)-2-(ETHYLAMINO)PENTAN-1-ONE; 1-(BENZO[D][1,3]DIOXOL-5-IL)-2-(ETHYLAMINO)PENTAN-1-ONE
161.	PARAHEXYL	or	3-HEXYL-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO[B,D]PYRANE-1-OL
162.	PENTEDRONE	or	2-(METHYLAMINO)-1-PHENYL-PENTAN-1-ONE
163.	PENTYLONE	or	BK-MBDP; BK-MBDP; BK-METHYL-K; 1-(BENZO[D][1,3]DIOXOL-5-IL)-2-(METHYLAMINO)PENTAN-1-ONE
164.	PMA	or	P-METHOXY-ALPHA-METHYLPHENETYLAMINE
165.	PMMA	or	PARA-METHOXYMETHAMPHETAMINE; [1-(4-METHOXYPHENYL)PROPANE-2-YL](METHYL)AZANE]
166.	PSYLOCYBIN	or	3-[2-(DIMETHYLAMINOETHYL)]INDOL-4-YLO DIHYDROGENATED PHOSPHATE
167.	PSILOCIN	or	PSYLOTSIN; 3-[2-(DIMETHYLAMINO)ETHYL]INDOL-4-OL

168.	RH-34	or	3-(2-((2-METHOXYBENZYL)AMINO)ETHYL)QUINAZOLINE-2,4(1H,3H)-DIONE
169.	ROLICYCLIDINE	or	PHP; PCPY; 1-(1-PHENYLCYCLOHEXYL)PYRROLIDINE
170.	SALVINORIN A	or	METHYL(2S,4AR,6AR,7R,9S,10AS,10BR)-9-ACETOXY-2-(3-FURYL)-6A,10B-DIMETHYL-4,10-DIOXODODECAHYDRO-2H-BENZO[F]ISOCHROMENE-7-CARBOXYLATE
171.	STP	or	DOM ; 2,5-DIMETHOXY-ALPHA,4-DIMETHYLPHENETHYLAMINE
172.	TENAMPHETAMINE	or	MDA; ALPHA-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE
173.	TENOCYCLIDINE	or	TCP ; 1-[1-(2-THIENYL)CYCLOHEXYL]PIPERIDINE
174.	TETRAHYDROCANNABINOL	or	THC
175.	TH-PVP	or	2-(PYRROLIDIN-1-IL)-1-(5,6,7,8-TETRAHIDRONAPHTHALEN-2-IL)PENTAN-1-ONE
176.	TMA	or	(±)-3,4,5-TRIMETHOXY-ALPHA-METHYLPHENETYLAMINE
177.	TFMPP	or	1-(3-TRIFLUORMETHYPHENYL)PIPERAZINE
178.	UR-144	or	(1-PENTYL-1H-INDOL-3-IL) (2,2,3,3-TETRAMETHYLCYCLOPROPYL)-METHANONE
179.	XLR-11	or	5F-UR-144; [1-(5-FLUOROPENTYL)-1H-INDOL-3-YL](2,2,3,3-TETRAMETHYLCYCLOPROPYL)-METHANONE
180.	ZIPEPROL	or	ALPHA-(ALPHA-METHOXYBENZYL)-4-(BETA-METHOXYPHENETHYL)-1-PIPERAZINEETHANOL


b) STRUCTURAL CLASSES OF SYNTHETIC CANNABINOIDS – Cannabimimetic substances that fall into the following structural classes are also controlled by this List:

1. Any substance that presents a 2-(cyclohexyl)phenol structure (structure B1):

1.1. With substitution in the phenoxy ring (-R1), forming a hydroxyl, alkoxy (ether) or carboxyalkyl (ester) group;


1.2. The formation of a cycle between -R1 and other substituents does not fall within the structure;

- 1.3. Substituted on the phenoxy ring (-R2);
- 1.4. Substituted or not on the cyclohexyl ring (-R3);
- 1.5. Substituted or not on the cyclohexyl ring (-R4);
- 1.6. Which may or may not present unsaturation in any position of the cyclohexyl ring;
- 1.7. Substituted or not on the phenoxy ring (-R5), in any position, by one or more substituents.



2. Any substance having a naphthalen-1-yl(1H-indol-3-yl)methanone (structure B2), or naphthalen-1-yl(1H-indol-3-yl)methane (structure B3), or naphthalen-1-yl(1H-indazol-3-yl)methanone (structure B4) structure:

- 2.1. Substituted on the nitrogen atom of the indole or indazole ring (-R1);
- 2.2. Substituted or not on the indole ring (-R2);
- 2.3. Substituted or not on the indole or indazole ring (-R3), in any position, by one or more substituents;
- 2.4. Substituted or not, by a substituent on each of the rings of the naphthalene system (-R4 and -R5), in any position.
- 2.5. The formation of a cycle between -R4 and -R5 is not included in the structure.




3. Any substance that has a naphthalen-1-yl(1H-pyrrol-3-yl)methanone structure (structure B5):

3.1. Substituted on the nitrogen atom of the pyrrole ring (-R1);

3.2. Substituted or not on the pyrrole ring (-R2), in any position, by one or more substituents;

3.3. Substituted or not, by a substituent, on each of the rings of the naphthalene system (-R3 and -R4), in any position;

3.4. The formation of a cycle between -R3 and -R4 is not included in the structure.



4. Any substance that presents a phenyl(1H-indol-3-yl)methanone (structure B6) or phenyl(1H-indol-3-yl)ethanone (structure B7) structure:


4.1. Substituted on the nitrogen atom of the indole ring (-R1);

4.2. The formation of a cycle between -R1 and other substituents is not included in the structure;

4.3. Substituted or not on the indole ring (-R2);


4.4. Substituted or not on the indole ring (-R3), in any position, by one or more substituents;

4.5. Substituted or not on the phenyl ring (-R4), in any position, by one or more substituents.



5. Any substance that has a cyclopropyl(1H-indol-3-yl)methanone (structure B8) or cyclopropyl(1H-indazol-3-yl)methanone (structure B9) structure:


- 5.1. Substituted on the nitrogen atom of the indole or indazole ring (-R1);
- 5.2. The formation of a cycle between -R1 and other substituents is not included in the structure;
- 5.3. Substituted or not on the indole ring (-R2);
- 5.4. Substituted or not on the indole or indazole ring (-R3), in any position, by one or more substituents;
- 5.5. Substituted or not on the cyclopropyl ring (-R4, -R5, -R6, -R7), by one or more substituents.



6. Any substance that presents a 1H-indazole-3-carboxamide (structure B10) or 1H-indole-3-carboxamide (structure B11) structure:

- 6.1. Substituted on the nitrogen atom of the indazole or indole ring (-R1);
- 6.2. The formation of a cycle between -R1 and other substituents is not included in the structure;
- 6.3. Substituted or not on the indole ring (-R2);
- 6.4. Substituted or not on the indazole or indole ring (-R3), in any position, by one or more substituents;

6.5. Substituted or not on the carboxamide group (-R4 and -R5), by one or two substituents.



7. Any substance having a quinolin-8-yl(1H-indol-3-yl)carboxylate (structure B12), or quinolin-8-yl(1H-indazol-3-yl)carboxylate (structure B13), or naphthalen-1-yl(1H-indol-3-yl)carboxylate (structure B14), or naphthalen-1-yl(1H-indazol-3-yl)carboxylate (structure B15) structure:

7.1. Substituted on the nitrogen atom of the indole or indazole ring (-R1);


7.2. The formation of a cycle with -R1 does not fit into the structure;

7.3. Substituted or not on the indole ring (-R2);

7.4. Substituted or not on the indole or indazole ring (-R3), in any position, by one or more substituents;

7.5. Substituted or not, by a substituent in each of the rings of the quinoline or naphthalene system (-R4 and -R5), in any position.

7.6. The formation of a cycle between -R4 and -R5 is not included.



c) STRUCTURAL CLASS OF SYNTHETIC CATHINONES – Synthetic cathinones that fall into the following structural class are also controlled by this List:

1. Any substance that has a 2-aminopropan-1-one structure (structure C1):

1.1. Substituted at the carbonyl carbon atom (position 1) by benzene or benzene fused to other cycles;

1.2. Substituted or not at the benzene or in the fused ring system by one or more substituents (-R1), in any position, by alkyl, alkoxy, haloalkyl, halide, or hydroxy groups;

1.2.1. The formation of a cycle with -R1 does not fall within the structure.


1.3. Substituted or not at the nitrogen atom (-R2 and -R3) by one or two alkyl, aryl, or alkyl-aryl groups or by inclusion of the nitrogen atom in a cyclic structure;

1.4. Substituted or not in position 2 (-R4) by a methyl group.

1.4.1. The formation of a cycle with -R4 does not fit into the structure.

1.5. Substituted or not in position 3 (-R5) by an alkyl group.

1.5.1. The formation of a cycle with -R5 does not fit into the structure.



d) STRUCTURAL CLASSES OF PHENYLETHYLAMINES – Phenylethylamines that fall into the following structural classes are also controlled by this List:

1. Any substance that has a 1-phenylethan-2-amine structure (structures D1 and D2):

1.1. Substituted in the benzene ring:

1.1.1. at -R6 and -R7, by two alkyl or haloalkyl groups in structure D1; or

1.1.2. at -R6 and -R7, by one alkyl group and one haloalkyl group in structure D1; or


1.1.3. at adjacent carbons, resulting in the formation of one or two furan, dihydrofuran, tetrahydrofuran, pyran, dihydropyran, pyrrole, methylenedioxy, or ethylenedioxy groups in structure D2.

1.2. Additionally, substituted or not in the benzene ring (-R5), in any position, by one or more alkoxy, alkyl, alkenyl, alkynyl, halide, haloalkyl, hydroxy, nitro, seleniumalkyl, or thioalkyl substituents;

1.3. Substituted or not in position 1 (-R4), by acetyl, alkoxy, alkyl, cycloalkyl, or hydroxy groups;

1.4. Substituted or not, in position 2 (-R3), by an alkyl group;

1.5. Substituted or not, by one or two substituents, on the nitrogen atom (-R1 and -R2), by acetyl, alkyl, benzyl, benzyl substituted in one or more positions, hydroxy, hydroxy-alkyl groups, or by the inclusion of the nitrogen atom in a cyclic structure.




2. Any substance that presents a 1-phenylpropan-2-amine structure (structure D3):

2.1. Substituted or not, in any position, in the benzene ring, by one or more alkoxy, alkyl, cycloalkyl, halide, haloalkyl, hydroxy, nitro, seleniumalkyl, or thioalkyl substituents (-R5);

2.2. Substituted or not, in position 1 (-R4), by acetyl, alkoxy, alkyl, cycloalkyl, or hydroxy groups;

2.3. Substituted or not, in position 3, by an alkyl group (-R3);

2.4. Substituted or not, by one or two substituents, on the nitrogen atom (-R1 and -R2), by alkyl, acetyl, hydroxy, hydroxy-alkyl, benzyl, benzyl substituted in any position, or by the inclusion of the nitrogen atom in a cyclic structure.



ADDENDUM:

1) The following are also controlled:

1.1. Whenever their existence is possible, all salts and isomers of the substances in this List.

1.2. The following isomers and their stereochemical variants of the substance tetrahydrocannabinol:

7,8,9,10-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol

(9R,10aR)-8,9,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol

(6aR,9R,10aR)-6a,9,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol

(6aR,10aR)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol

6a,7,8,9-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol

(6aR,10aR)-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-9-methylene-3-pentyl-6H-dibenzo[b,d]pyran-1-ol

- 2) The phentermine isomer, which is listed in List "B2" of this Regulation, is excluded from the controls relating to this List.
- 3) The substance cannabidiol, which is listed in List "C1" of this Regulation, is excluded from the controls relating to this List.
- 4) The substance ropivacaine is exempt from the legal provisions of this Technical Regulation.
- 5) The substance milnacipran, which is listed in list "C1" of this Regulation, is exempt from the controls related to this List.
- 6) The medicinal products granted marketing authorization by Anvisa that contain the substance tetrahydrocannabinol (THC) in their formulation are exempt from the controls related to this List, provided that the requirements to be regulated prior to granting marketing authorization are met.
- 7) The isomers of the substances classified in items "b", "c", or "d" are exempt from the controls related to this List, provided that these isomers do not fit into any of the structural classes described in said items and are not isomers of substances described by name in item "a" of this List.
- 8) Any substances that are described by name in the lists of this Regulation are exempt from the controls related to items "b", "c", and "d".
- 9) The metazocine isomer, which is listed in List "A1" of this Regulation, is exempt from the controls related to this List.
- 10) The substance mepivacaine is exempt from the legal provisions of this Technical Regulation.
- 11) The phendimetrazine isomer, which is listed in List "B2" of this regulation, is exempt from the controls related to this List.
- 12) The substance DEET (N,N-diethyl-3-methylbenzamide) is exempt from the legal provisions of this Technical Regulation.
- 13) The pentazocine isomer, which is listed in List "B1" of this Regulation, is exempt from the controls related to this List.
- 14) The isomers listed by name in another List of this Regulation are exempt from the controls related to this List.

15) The components of medicinal products granted marketing authorization by Anvisa that fall under items "b", "c", or "d", as well as medicinal products that contain them, are excluded from the controls relating to this List.

16) The import and export of analytical standards based on the substances 1B-LSD, 1cP-LSD, 1P-LSD, 2C-C, 2C-D, 2C-E, 2C-F, 2C-I, 2C-T-2, 2C-T-7, 2-MEO-DIPHENIDINE, 3-FLUOROPHENMETRAZINE, 3-MeO-PCP, 4-AcO-DMT, 4AcO-MET, 4-BROMOMETCATINONE, 4-CL-ALPHA-PVP, 4-CHLOROMMETCATINONE, 4-FLUOROMETCATINONE, 4-HO-MIPT, 4-MEAPP, 5-APB, 5-APDB, 5C-MDA-19, 5-EAPB, 5F-AB-PFUPPYCA, 5F-MDA-19, 5-IAI, 5-MAPDB, 5-MeO-AMT, 5-MeO-DALT, 5-MeO-DIPT, 5-MeO-DMT, 5-MeO-MIPT, 25B-NBOH, 25C-NBF, 25C-NBOH, 25D-NBOME, 25E-NBOH, 25E-NBOME, 25H-NBOH, 25H-NBOME, 25I-NBF, 25I-NBOH, 25N-NBOME, 25P-NBOME, 25T2-NBOME, 25T4-NBOME, 25T7-NBOME, 30C-NBOME, ADB-5Br-INACA, ADB-FUBIATA, ADB-INACA, AKB48, ALD-52, ALFA-EAPP, ALFA-D2PV, AMT, BETACETO-DMBDB, BZO-4en-POXIZID, BZO-CHMOXIZID, BZO-HEPOXIZID, CH-PIATA, CLOBENZOREX, DIHYDRO-LSD, DIPHENIDINE, DIMETHYLONE, DMAA, DMBA, DOC, DOI, EAM-2201, ERGINE, JWH-071, JWH-072, JWH-081, JWH-098, JWH-122, JWH-210, JWH-250, JWH-251, JWH-252, JWH-253, MAM-2201, MAM-2201 N-(4-HYDROXIPENTYL), MAM-2201 N-(5-CHLOROPENTYL), MCPP, MDA-19, MDAI, MDMB-5Br-INACA, MDMB-INACA, METALLYLESCALINE, N-ACETYL-3,4-MDMC, N-ETHYLCATHIONE, N-ETHYLHEXEDRON, PENTYLONE, RH-34, SALVINORIN A, TH-PVP, and TFMPP, in which the quantity of the active ingredient subject to special control does not exceed 500 mg per unit, do not require Import Authorization and Export Authorization, respectively. The provisions of this addendum also apply to analytical standards based on salts and isomers of the aforementioned substances, unless they are explicitly excepted or included in more restricted control lists and provided that the quantity of the active ingredient subject to special control does not exceed the specified limit.

17) isomers not listed by name and which are components of medicines registered with Anvisa, as well as medicines containing them, are excluded from the controls related to this list. LIST F3 - PRECURSOR SUBSTANCES

1. Phenylpropanolamine or norephedrine

ADDENDUM:

1) all salts and isomers of the substances listed above are also under control, whenever their existence is possible.

2) isomers listed by name in another List of this regulation are excluded from the controls related to this List.

3) isomers not listed by name and which are components of medicinal products granted marketing authorization by Anvisa, as well as medicinal products containing them, are excluded from the controls related to this List.

LIST F4 – OTHER SUBSTANCES

1. Dexfenfluramine

2. Dinitrophenol

3. Strychnine
4. Etretinate
5. Fenfluramine
6. Lindane
7. Terfenadine

ADDENDUM:

- 1) all salts and isomers of the substances listed above are also controlled, whenever their existence is possible.
- 2) Lindane is authorized to be used as an analytical standard for laboratory purposes or for monitoring environmental residues, in accordance with specific legislation.
- 3) Isomers listed by name in another List of this regulation are exempt from the controls related to this List.
- 4) The import and export of analytical standards based on substances included in this list, in which the quantity of the active ingredient subject to special control does not exceed 500 mg per unit, do not require an Import Authorization and an Export Authorization, respectively. The provisions of this addendum also apply to analytical standards based on the salts and isomers of the substances, unless they are explicitly excepted or included in more restrictive control lists and provided that the quantity of the active ingredient subject to special control does not exceed the specified limit.
- 5) Isomers not listed by name and which are components of medicinal products granted marketing authorization by Anvisa, as well as medicinal products containing them, are exempt from the controls related to this List.